65,437 trials
Healthy Adult Immune Responses to Vaccine
Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants
Frailty Syndrome
Primary: Change in the Short Physical Performance Battery (SPPB) — 0.6; 2.4 units on a scale
Cognitive Impairment
Primary: Ratio of Psychosocial and Socio-emotional Statements Relative to Biomedical Talk and Orientation Statements (Patient-Centered Communication) — 0.86; 0.68 Ratio — p=0.046
Chronic Obstructive Pulmonary Disease
Primary: Length of Stay — 4.8; 3.2 days
Metastatic Prostate Cancer
Primary: Recommended Phase 2 Dose (RP2D) — 25 mg
HIV · Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants
Chronic Pain
Primary: Intervention Feasibility: Median Number of Study Intervention Sessions Attended by Participants — 9 Study Sessions
Macular Edema
Primary: Change From Baseline to Week 52 in NEI VFQ-25 Total Score — 6.106 score on a scale
Delirium · Psychomotor Agitation · Substance Withdrawal Syndrome
Primary: 30-day Mortality — 9.5; 7.7 percentage of patients
Atrial Fibrillation
Primary: Number of Participants Who Developed Postoperative Atrial Fibrillation — 33; 30 participants — p=<0.01
HIV (Human Immunodeficiency Virus)
Primary: Change in Symptom Status From Baseline to Week 12 — -0.858; -0.318; -0.541; -0.570 score on a scale — p=0.001
The Frailty Syndrome
Primary: Treatment Emergent Adverse Events — 1; 0; 1; 0 Events
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI — 0.91; 1.07; 1.21 Exacerbations per participant per year — p=<0.001
Multiple Myeloma
Primary: Cmax (Pharmacokinetics) — 7380 ng/ml
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of Evacetrapib (Fasted) — 14600; 14600 nanogram·hour/milliliter (ng·h/mL)